Deferasirox
Clinical data | |
---|---|
Pronunciation | de FER a sir ox |
Trade names | Exjade, Jadenu |
Other names | CGP-72670, ICL-670A, IC L670 |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 70% |
Protein binding | 99% |
Metabolism | Hepatic glucuronidation |
Elimination half-life | 8 to 16 hours |
Excretion | Fecal (84%) and renal (8%) |
Identifiers | |
| |
JSmol) | |
Density | 1.4±0.1 g/cm3 [2] |
| |
| |
(what is this?) (verify) |
Deferasirox, sold under the brand name Exjade & Asunra (in injectable form) & Oleptiss (Tablet formulation) both by
It was approved by the U.S. Food and Drug Administration (FDA) in November 2005.[3][5] According to the FDA (May 2007), kidney failure and cytopenias have been reported in patients receiving deferasirox tablets for oral suspension. It is approved in the European Union by the European Medicines Agency (EMA) for children six years and older for chronic iron overload from repeated blood transfusions.[6][7][8] It is on the World Health Organization's List of Essential Medicines.[9]
In July 2020, Teva decided to discontinue deferasirox.[10] It is available as a generic medication.[11]
Properties
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which are subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Synthesis
Deferasirox can be prepared from simple commercially available starting materials (salicylic acid, salicylamide and 4-hydrazinobenzoic acid) in the following two-step synthetic sequence:
The condensation of salicyloyl chloride (formed in situ from salicylic acid and thionyl chloride) with salicylamide under dehydrating reaction conditions results in formation of 2-(2-hydroxyphenyl)-1,3(4H)-benzoxazin-4-one. This intermediate is isolated and reacted with 4-hydrazinobenzoic acid in the presence of base to give 4-(3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl)benzoic acid (deferasirox).[12]
Risks
Deferasirox ranked second on the list of drugs most frequently suspected in reported patient deaths compiled for 2019 by the Institute for Safe Medical Practices, with 1320 suspected deaths.[13] A boxed warning was added in the same year with regard to kidney failure, liver failure and gastrointestinal bleeding.[14] It is suspected that the main driver of this spike in suspected deaths relates to the re-analysis of adverse event data by Novartis.[13]
References
- FDA. Retrieved 22 Oct 2023.
- ^ "Material Safety Data Sheet (MSDS): Deferasirox". ChemSrc. 2018.
- ^
- S2CID 195686285.
- ^ a b "FDA Approves First Oral Drug for Chronic Iron Overload" (Press release). United States Food and Drug Administration. November 9, 2005. Retrieved 2007-10-31.
- ^ "Exjade – deferasirox" (PDF). European Medicines Agency. 2018. Archived from the original (PDF) on 2017-12-29. Retrieved 2012-11-26.
- S2CID 27794849.
- ^ "Review: Exjade side effects". Archived from the original on 2016-03-04. Retrieved 2013-04-20.
- hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "Deferasirox Discontinuation". U.S. Food and Drug Administration (FDA). Retrieved 20 July 2020.
- ^ "Drugs@FDA: FDA-Approved Drugs". U.S. Food and Drug Administration. Retrieved 15 August 2020.
- .]
- ^ a b "QuarterWatch™ (Quarter 4 and 2009 totals): Reported Patient Deaths Increased by 14% in 2009". Institute For Safe Medication Practices. Retrieved 2021-06-28.
- ISSN 1073-0397. Archived from the original on 2021-06-28. Retrieved 2021-06-28.)
{{cite journal}}
: CS1 maint: DOI inactive as of January 2024 (link